Okami Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Okami Medical is a commercial-stage medical device company specializing in peripheral vascular occlusion. Its core innovation is the LOBO Occluder, which utilizes proprietary High-Density Braid (HD BRAID) technology to achieve faster and more consistent occlusion compared to traditional coils and plugs. The company is targeting a significant segment of the embolization market by offering a single-device solution for a wide range of vessel diameters, supported by its optimized SENDERO delivery catheters. As a private company, it is positioned to capture market share in interventional radiology and related specialties.

Peripheral Vascular DiseaseInterventional Radiology

Technology Platform

Proprietary HD BRAID (High-Density Braid) technology using sub-20-micron wires to create small-pore, self-expanding nitinol occlusive devices for rapid vascular occlusion.

Opportunities

The LOBO device addresses a large and growing peripheral embolization market by offering a faster, single-device alternative to multiple coils or plugs, potentially reducing procedure time and cost.

Its versatility across a wide vessel range (1.5-9mm) with only four sizes simplifies hospital inventory and purchasing.

Successful clinical adoption could position Okami as an acquisition target for larger medtech companies seeking innovative vascular occlusion technology.

Risk Factors

Okami faces intense competition from established giants with dominant market share and deep physician relationships.

As a new technology, broad clinical validation beyond initial claims is needed to drive adoption, and any real-world performance issues could severely impact growth.

Being a private, early-commercial company, it carries financial execution risk and dependence on continued capital access to fund its commercial rollout.

Competitive Landscape

Okami competes in the peripheral vascular embolization market against major players like Boston Scientific, Terumo, and Stryker (coils) and Abbott (vascular plugs). Its primary competitive differentiation is the HD BRAID technology, which it claims enables faster, more complete occlusion with a single device compared to traditional coil packs or plug designs. The competitive threat includes both the inertia of established practice and the continuous innovation from these large, well-resourced competitors.

More companies in Digital Health & Biotech SaaS →More companies in United States →